Cellectar Biosciences and NorthStar Medical Radioisotopes have signed a strategic supply agreement for the procurement of NorthStar’s non-carrier added (n.c.a.) Ac-225, the company announced today.

“We plan to advance CLR 121225 into human clinical trials in 2025 as part of a broader strategy to bring first-and best-in-class radiotherapeutics to market,” Cellectar President and CEO James Caruso said in a statement. “This agreement with NorthStar provides a reliable source of Ac-225, which is a critical to our clinical development strategy.”

According to a release, the agreement supplies Ac-225 from NorthStar for 10 years and is expected to start in 2025.